The Somerset laboratory, by the record
Current good manufacturing practice (cGMP) analytical studies completed
Good Laboratory Practice (GLP) bioanalytical studies completed
Years in business, founded in 2006
Square foot facility with 14 LC-MS/MS systems
Procurement from a global network of qualified API partners, with regulatory and market intelligence behind the selection.
Method development and validation, impurity work, and release and stability testing of APIs and drug products, clinical through commercial.
Drug and metabolite quanititation in biological matrices supporting PK, TK, bioequivalence, and immunogenicity programs.
“Sannova gives us a U.S. based team that develops and validates its methods at the center of the Northeast pharmacautical corridor. This acquisition provides additional capabilities, but also adds capacity for the growing volume of work our clients are bringing to us.ˮ
Chief Executive Officer, LGM Pharma
“Our clients chose Sannova for the people and methods behind their data, and those stay in place. LGM Pharmaʼs backing lets us continue investing in our scientists, instruments, capacity, and client services faster than we could independently.ˮ
President and Chief Executive Officer, Sannova Analytical
Two pages on what the Somerset laboratory runs, the standards each service is validated to, and the instruments behind it. Open it here or download the PDF.
Nitrosamines and NDSRIs, extractables and leachables, elemental impurities, method development and validation, and release and stability testing, with the USP and ICH standards each is validated to.
PK, TK, and DMPK, immunogenicity and ADA, ligand binding, nanoparticles and metalloproteins, and cell and gene therapy assays, validated to ICH M10 from preclinical through Phase 4.